VIDAS床旁检测超敏肌钙蛋白I的临床应用评价被引量：3

下载PDF

导出

摘要急性心肌梗死（AMI）目前已成为最常见的心肌疾病.肌钙蛋白I（cTnI）在起病3～4小时后升高,于11～24小时达高峰,7～10天降至正常.高敏感心肌肌钙蛋白（hs-cTnI）是目前反映心肌损伤最敏感和特异的生物学标志物,广泛应用于AMI的早期诊治[1].目前检测hs-cTnI方法和仪器多种多样,随着床旁检测（POCT）技术的不断完善和推广,同一医院根据不同的检测需求配置的设备不尽相同.由于POCT准入门槛及技术要求较低,检验质量的标准化尚未建立,检验结果正确性有待评估.笔者根据本院检验科西门子ADVIA centaur XP化学发光免疫分析系统（CLIA）检测hs-cTnI为参比方法,按照ISO15189《医学实验室质量和能力认可》的要求[2],依据美国国家临床实验室标准化协会（NCCLS） EP5-A2和EP9-A2文件,对心血管内科及急诊科VIDAS酶联荧光免疫分析（ELFA）系统检测的hs-cTnI从精密度和准确度两个方面分别进行评估,以观察VIDAS POCT是否能够满足临床需求.

作者王坤崔建设郭亚琼

机构地区河南科技大学附属黄河三门峡医院检验科

出处《标记免疫分析与临床》 CAS 2016年第9期1091-1094,共4页 Labeled Immunoassays and Clinical Medicine

关键词 VIDAS床旁检测系统超敏肌钙蛋白I

分类号 R446.1 [医药卫生—诊断学] R542.22 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献9

1鄢盛恺.高敏感心肌肌钙蛋白检测的临床应用[J].中华检验医学杂志,2010,33(9):809-813. 被引量：28
2中国合格评定国家认可委员会.医学实验室质量和能力认可准则(ISO 15189:2007).2008.
3王建新,孙长江.肌钙蛋白报告周转时间延长分析[J].检验医学与临床,2013,10(10):1314-1315. 被引量：4
4丛玉隆.POCT的临床应用与存在的问题[J].中华检验医学杂志,2007,30(12):1325-1328. 被引量：81
5Kavsak P A, Wang X, Ko D T, et al. Short and long term riskstratification using a next- generation, high- sensitivity research cardiactroponin I ( hs-cTnl) assay in an emergency department chest painpopulation. Clin Chem,2009,55( 10) : 1809-1815.
6Katrukha A G, Bereznikova A V, Esakova T V, et al. Troponin I isreleased in bloodstream of patients with acute myocardial infarctionnot in free form but as complex. Clin Chem ,1997 ,43(8 Pt 1 ) : 1379-1385.
7Apple F S, Koplen B, Murakami M M. Preliminary evaluation of theVitros Eci cardiac troponin I assay. Clin Chem, 2000,46 (4):572-574.
8Christenson R H, Duh S H, Apple F S, et al. Standardization ofcardiac troponin I assay : round Robin of ten candidate referencematerials. Clin Chem,2001,47(3 ) :431-437.
9韩雪松,李强,丛进阳.心肌肌钙蛋白I检测及临床诊断标准化进展[J].中华检验医学杂志,2004,27(3):197-200. 被引量：72

二级参考文献52

1潘柏申,杨振华,吴健民.冠状动脉疾病和心力衰竭时心脏标志物临床检测应用建议[J].中华检验医学杂志,2006,29(9):774-778. 被引量：73
2Morrow DA,Cannon CP,Jesse RL,et al.National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines:clinical characteristics and utilization of biochemical markers in acute coronary syndromes.Clin Chem,2007,53:552-574.
3James S,Flodin M,Johnston N,et al.The antibody configurations of cardiac troponin I assays may determine their clinical performance.Clin Chem,2006,52:832-837.
4Christenson RH,Duh SH,Apple FS,et al.Toward standardization of cardiac troponin I measurements part Ⅱ:assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays.Clin Chem,2006,52:1685-1692.
5Cobbaert CM,Weykanp CW,Michielsen EC,et al.Timedependent instability of cardiac troponins in human plasma spiked with NIST reference material 2921.Clin Chem,2008,54:2078-2079.
6Panteghini M,Bunk DM,Christenson RH,et al.Standardization of troponin I measurements:an update.Clin Chem Lab Med,2008,46:1501-1506.
7Tate JR,Bunk DM,Christenson RH,et al.Standardization of cardiac troponin I measurement:past and present.Pathology,2010,42:402-408.
8Alpert JS,Thygesen K,Antman E,et al.Myocardial infarction redefined:a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction.J Am Coll Cardio1,2000,36:959-969.
9Thygesen K,Alpert JS,White HD,et al.Universal definition ofmyocardial infarction.Circulation,2007,116:2634-2653.
10Apple FS.A new season for cardiac troponin assays:it's time to keep a scorecard.Clin Chem,2009,55:1303-1307.